World Ovarian Cancer Coalition. Global ovarian cancer charter data briefing. Accessed January 1, 2024. Available at: https://worldovariancancercoalition.org/wp-content/uploads/2022/02/Global-Priority_Final.pdf

• PubMed
World Ovarian Cancer Coalition. Global ovarian cancer charter data briefing. Accessed January 1, 2024. Available at: https://worldovariancancercoalition.org/wp-content/uploads/2022/02/Global-Priority_Final.pdf)| false
• Search Google Scholar
• Export Citation

Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397:2182–2193.

• PubMed
Menon U, Gentry-Maharaj A, Burnell M, Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397:2182–2193.)| false
• Search Google Scholar
• Export Citation

Cabasag CJ, Butler J, Arnold M, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecol Oncol 2020;157:234–244.

• PubMed
Cabasag CJ, Butler J, Arnold M, Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecol Oncol 2020;157:234–244.)| false
• Search Google Scholar
• Export Citation

Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2:482–490.

• PubMed
Norquist BM, Harrell MI, Brady MF, Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2:482–490.)| false
• Search Google Scholar
• Export Citation

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402–2416.

• PubMed
Kuchenbaecker KB, Hopper JL, Barnes DR, Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402–2416.)| false
• Search Google Scholar
• Export Citation

DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023;41:609–617.

• PubMed
DiSilvestro P, Banerjee S, Colombo N, Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023;41:609–617.)| false
• Search Google Scholar
• Export Citation

Møller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA mutations—family history detects less than 50% of the mutation carriers. Eur J Cancer 2007;43:1713–1717.

• PubMed
Møller P, Hagen AI, Apold J, Genetic epidemiology of BRCA mutations—family history detects less than 50% of the mutation carriers. Eur J Cancer 2007;43:1713–1717.)| false
• Search Google Scholar
• Export Citation

Manchanda R, Sun L, Sobocan M, et al. Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. J Natl Compr Canc Netw 2024;22:e237331.

• PubMed
Manchanda R, Sun L, Sobocan M, Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. J Natl Compr Canc Netw 2024;22:e237331.)| false
• Search Google Scholar
• Export Citation

Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796–797.

• PubMed
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796–797.)| false
• Search Google Scholar
• Export Citation

Kwon JS, Tinker AV, Santos J, et al. Germline testing and somatic tumor testing for BRCA1/2 pathogenic variants in ovarian cancer: what is the optimal sequence of testing? JCO Precis Oncol 2022;6:e2200033.

• PubMed
Kwon JS, Tinker AV, Santos J, Germline testing and somatic tumor testing for BRCA1/2 pathogenic variants in ovarian cancer: what is the optimal sequence of testing? JCO Precis Oncol 2022;6:e2200033.)| false
• Search Google Scholar
• Export Citation

Schrag D, Kuntz KM, Garber JE, et al. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465–1471.

• PubMed
Schrag D, Kuntz KM, Garber JE, Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465–1471.)| false
• Search Google Scholar
• Export Citation

Hanley GE, Pearce CL, Talhouk A, et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 2022;5:e2147343.

• PubMed
Hanley GE, Pearce CL, Talhouk A, Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 2022;5:e2147343.)| false
• Search Google Scholar
• Export Citation

Kaur P, Rufin K, Finlayson SJ, et al. Opportunistic salpingectomy between 2017 and 2020: a descriptive analysis. J Obstet Gynaecol Can 2024;46:102278.

• PubMed
Kaur P, Rufin K, Finlayson SJ, Opportunistic salpingectomy between 2017 and 2020: a descriptive analysis. J Obstet Gynaecol Can 2024;46:102278.)| false
• Search Google Scholar
• Export Citation